Evidence accrues for SBRT over conventional radiation for prostate outcomes

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

FDA gives RaySearch green light for RayStation 8B platform First treatment planning system to offer machine learning applications

MedAustron to add health IT to proton and carbon ion treatment facilities Orders more than $13 million worth of RaySearch systems

'Nudge' in EHRs cuts imaging in half for palliative radiotherapy, says study Reduces duration of radiotherapy sessions

Mayo Clinic Florida campus to get $233 million proton facility The 140,000-square-foot facility will house a two-gantry proton system

Demand on the rise for MR-guided radiotherapy, says new report Compound annual growth rate of 20 percent through 2028

New proton therapy center planned in Russia Investment calls for 7.5 billion rubles to bring greater cancer care to patients

NYC proton facility opens for business $300 million dollar, 140,000 square-foot facility was ten years in the making

Bill aiming to reduce prior authorization delays for cancer treatment introduced in Congress Supporting timely access to care

Roche and GE Healthcare release NAVIFY Tumor Board 2.0 Supports personalized treatment decision-making

Cancer mortality for men, women and children on the decline, says report Decreased by 1.8 percent in men and 1.4 percent in women

Courtesy: University of Texas

Evidence accrues for SBRT over conventional radiation for prostate outcomes

by Lee Nelson , Contributing Reporter
Men are getting good news when it comes to determining the best options for treating prostate cancer, according to a five-year study of Stereotactic Body Radiation Therapy (SBRT) conducted at University of Texas Southwestern Medical Center. The study — the first trial to publish results over that length of time — revealed better than expected outcomes.

“We were surprised by the 98.6 percent cure rate. We did not expect to have such high numbers at five years,” Dr. Raquibul Hannan, assistant professor of radiation oncology at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center in Dallas, and lead author of the study, told HCB News. “We were expecting to find numbers around 90 percent, with the main advantage of maximizing the patient convenience of five treatments compared to the 44 treatments required for conventional radiation therapy.”

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Out of the 91 patients treated in the study, only one patient experienced a recurrence of his cancer. The study reported that doctors examined the patient carefully and realized that the failure was outside the radiation field. “This suggests that even in this patient, SBRT likely did its job of killing the cancer, but the cancer probably already had metastasized outside of the radiation field,” Hannan said.

The SBRT treatment of prostate cancer with a biogradable, injectable spacer gel to protect the rectum is now the standard of care at UT Southwestern, and it is offered to all eligible low- and intermediate-risk (stage I and II) prostate cancer patients routinely even outside of the clinical trial setting.

The Simmons facility utilizes a range of stereotactic radiotherapy modalities including Gamma Knife, CyberKnife, Agility, Vero SBRT and Varian's TrueBeam.

“We believe that this noninvasive, effective, convenient and relatively safe treatment option is the future of prostate cancer treatment,” Hannan said.

For high-risk patients where treatment of a larger field (including pelvic lymph nodes) is necessary, the SBRT five-fraction treatment is only available via a clinical trial that is currently enrolling patients at the institution, said Hannan. “We believe that this trial will also be successful in demonstrating the safety and efficacy of this approach for high-risk patients. However, this remains to be seen,” he added.

In the short term, SBRT side effects can include urinary issues and rectal irritation, which are often temporary and reverse within four weeks of the treatment. Erectile dysfunction was seen in 25 percent of patients, fewer than with conventional radiation or surgery, and there was a small risk of longer term urinary or rectal complications, according to Hannan.

Another benefit of using SBRT is increased patient convenience — which sometimes translates into feasibility. Some patients that are coming in from remote locations would not have been able to receive this treatment if it had not been given in five fractions.

“Less anxiety is also involved since the PSA response for this form of treatment is much faster, and within a few months after treatment there is already a significant drop in PSA. The cost of this is less than half of the 44 fraction treatment,” he said.

“Making patients and their care providers aware of the findings of this and other related studies is certainly going to be crucial. It is also clear that this is just one study with 91 patients. We will ideally need to have more studies with thousands of enrolled patients to be able to confirm this finding,” he said.

Hannan explained that they are now applying this SBRT technique to early stage kidney cancer in an ongoing clinical trial at his medical center. “We believe this will be an available option for patients in the future,” he said.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment